Supplementary Figure S2 from [89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma

Autor: Carla M.L. van Herpen, Wim J.G. Oyen, Erik H.J.G. Aarntzen, Winette T.A. van der Graaf, Gerben J.C. Zwezerijnen, Otto S. Hoekstra, Peter F.A. Mulders, Bertha Eisses, Adrienne H. Brouwers, Anne I.J. Arens, Astrid A.M. van der Veldt, C. Willemien Menke-van der Houven van Oordt, Ingrid M.E. Desar, Sandra Heskamp, Lindsay Angus, Sophie L. Gerritse, Suzanne C. van Es, Sjoerd G. Elias, Sjoukje F. Oosting, Sarah R. Verhoeff

Score chart with predicted probability (%) to remain on WW at 12 months This model was based on the number of IMDC Risk factors (0, 1, 2), the number or involved organ sites (0 - 4) and the geometric mean [¹⁸F]FDG SUVmax as a continuous variable.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::024dde545016efb5249512402f68978b
https://doi.org/10.1158/1078-0432.22489029

Supplementary Figure S1 from [89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma

Autor: Carla M.L. van Herpen, Wim J.G. Oyen, Erik H.J.G. Aarntzen, Winette T.A. van der Graaf, Gerben J.C. Zwezerijnen, Otto S. Hoekstra, Peter F.A. Mulders, Bertha Eisses, Adrienne H. Brouwers, Anne I.J. Arens, Astrid A.M. van der Veldt, C. Willemien Menke-van der Houven van Oordt, Ingrid M.E. Desar, Sandra Heskamp, Lindsay Angus, Sophie L. Gerritse, Suzanne C. van Es, Sjoerd G. Elias, Sjoukje F. Oosting, Sarah R. Verhoeff

Flow diagram of patient enrolment. * Four patients were unfit for systemic treatment due to clinical deterioration resulting from rapid disease progression (n=3) or comorbidity and age (n=1). Three other patients did not wat systemic treatment.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a286e4754487926332808b421d0032f3
https://doi.org/10.1158/1078-0432.22489032.v1

[89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma

Autor: Sarah R. Verhoeff, Sjoukje F. Oosting, Sjoerd G. Elias, Suzanne C. van Es, Sophie L. Gerritse, Lindsay Angus, Sandra Heskamp, Ingrid M.E. Desar, C. Willemien Menke-van der Houven van Oordt, Astrid A.M. van der Veldt, Anne I.J. Arens, Adrienne H. Brouwers, Bertha Eisses, Peter F.A. Mulders, Otto S. Hoekstra, Gerben J.C. Zwezerijnen, Winette T.A. van der Graaf, Erik H.J.G. Aarntzen, Wim J.G. Oyen, Carla M.L. van Herpen

Publikováno v: Clinical Cancer Research, 29, 592-601
Clinical cancer research : an official journal of the American Association for Cancer Research, 29(3), 592-601. American Association for Cancer Research Inc.
Clinical Cancer Research, 29(3). AMER ASSOC CANCER RESEARCH
Verhoeff, S R, Oosting, S F, Elias, S G, van Es, S C, Gerritse, S L, Angus, L, Heskamp, S, Desar, I M E, Menke-van der Houven van Oordt, C W, van der Veldt, A A M, Arens, A I J, Brouwers, A H, Eisses, B, Mulders, P F A, Hoekstra, O S, Zwezerijnen, G J C, van der Graaf, W T A, Aarntzen, E H J G, Oyen, W J G & van Herpen, C M L 2023, ' 89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma ', Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 29, no. 3, pp. 592-601 . https://doi.org/10.1158/1078-0432.CCR-22-0921, https://doi.org/10.1158/1078-0432.CCR-22-0921
Clinical Cancer Research : an official journal of the American Association for Cancer Research, 29(3), 592-601. American Association for Cancer Research Inc.
Clinical Cancer Research, 29, 3, pp. 592-601

Purpose: Watchful waiting (WW) can be considered for patients with metastatic clear-cell renal cell carcinoma (mccRCC) with good or intermediate prognosis, especially those with Experimental Design: Between February 2015 and March 2018, 48 patients w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efda010e4b9dc511b65f58abda2ef24e
http://hdl.handle.net/2066/291417

Prediction of watchful waiting in newly diagnosed metastatic clear cell renal cell carcinoma patients with a good or intermediate prognosis

Autor: Sarah R. Verhoeff, Peter F.A. Mulders, Lindsay Angus, Catharina Wilhelmina Menke, Suzanne C van Es, Erik H.J.G. Aarntzen, G.J.C. Zwezerijnen, Sjoukje F. Oosting, Sjoerd G. Elias, Astrid Aplonia Maria Van Der Veldt, Elisabeth G.E. de Vries, Sandra Heskamp, Sophie L. Gerritse, Anne I.J. Arens, Carla M.L. van Herpen, Adrienne H. Brouwers, Otto S. Hoekstra, Winette T. A. van der Graaf, Wim J.G. Oyen

Publikováno v: Journal of Clinical Oncology, 38(15). American Society of Clinical Oncology
Verhoeff, S, van Es, S C, Elias, S G, Gerritse, S, Angus, L, Oosting, S, Heskamp, S, Brouwers, A H, Arens, A I J, Menke, C W, Hoekstra, O S, Zwezerijnen, G J C, Van der Veldt, A A M, Mulders, P, Van der Graaf, W T A, De Vries, E, Oyen, W J G, Aarntzen, E H J G & Van Herpen, C M L 2020, ' Prediction of watchful waiting in newly diagnosed metastatic clear cell renal cell carcinoma patients with a good or intermediate prognosis. ', Journal of Clinical Oncology, vol. 38, no. 15 .
Journal of Clinical Oncology, 38(15). AMER SOC CLINICAL ONCOLOGY

5079 Background: In metastatic clear cell renal cell carcinoma (mccRCC), the number of International Metastatic Database Consortium (IMDC) risk factors plus metastatic sites may identify patients with rapid or slow disease progression in a period of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f0075b96d86c08b9afc4777a1f26ad1
https://research.vumc.nl/en/publications/98732163-7e52-4bc7-94c7-1dcf32962139

Comparative biodistribution analysis across four different 89Zr-monoclonal antibody tracers—The first step towards an imaging warehouse

Autor: C. Willemien Menke-van der Houven van Oordt, Suzanne C van Es, Michaël M. Smeenk, Johan R. de Jong, Carolina P. Schröder, Elisabeth G.E. de Vries, Frederike Bensch, Marjolijn N. Lub-de Hooge, Adrienne H. Brouwers, Ronald Boellaard, Sjoukje F. Oosting

Publikováno v: Bensch, F, Smeenk, M M, van Es, S C, de Jong, J R, Schröder, C P, Oosting, S F, Lub-de Hooge, M N, Menke-van der Houven van Oordt, C W, Brouwers, A H, Boellaard, R & de Vries, E G E 2018, ' Comparative biodistribution analysis across four different 89Zr-monoclonal antibody tracers-The first step towards an imaging warehouse ', Theranostics, vol. 8, no. 16, pp. 4295-4304 . https://doi.org/10.7150/thno.26370
Theranostics, 8(16), 4295-4304. Ivyspring International Publisher

Rationale: Knowledge on monoclonal antibody biodistribution in healthy tissues in humans can support clinical drug development. Molecular imaging with positron emission tomography (PET) can yield information in this setting. However, recent imaging s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ac1e985b080597ec390ac3883019096
https://doi.org/10.7150/thno.26370